Annexon (NASDAQ:ANNX) said it expects to report the month-15 primary-endpoint analysis from its Phase III ARCHER II trial of vonaprument in geographic atrophy, or GA, during the fourth quarter of 2026 ...
Annexon's stock hinges on the Q4 2026 readout of its Phase 3 ARCHER II trial's month-15 primary endpoint in geographic ...
12h
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 2026 Financial Results
Advancing a neuromuscular franchise with claseprubart, a highly potent, investigational classical pathway inhibitor, with best-in-disease potential across generalized Myasthenia Gravis (gMG), Chronic ...
Researchers model how shared qubits interfere in quantum computing, generalizing the Owicki–Gries method to account for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results